Benefits and risks of erythrocyte-stimulating agents

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 3

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Urology

ISSN

2219-2816

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Urol. Nov 24, 2014; 3(3): 258-263
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.258

Table 4 Nonhematologic complications associated with erythropoietin therapy[11]

Citation: Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263
URL: https://www.wjgnet.com/2219-2816/full/v3/i3/258.htm
DOI: https://dx.doi.org/10.5410/wjcu.v3.i3.258

Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263 [DOI: 10.5410/wjcu.v3.i3.258]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.